



CORRECTION

Correction to: Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms

Joe Yang · Jaesh Naik · Matthew Massello · Lewis Ralph · Ryan James Dillon

Published online: June 24, 2022
© The Author(s) 2022

Correction to: Infect Dis Ther
<https://doi.org/10.1007/s40121-022-00607-x>

In the original publication of the article,

1. In the third paragraph of ‘Results—Base Case’ section, the sentence “For patients treated with IMI/REL, we observed negative ICERs of – \$1988 per QALY gained, or – \$46,579 per death averted, or – \$26,521 per nephrotoxicity case averted.” Should be “For patients treated with IMI/REL, we observed negative ICERs of – \$2,996 per QALY gained, or – \$46,579 per death

averted, or – \$26,521 per nephrotoxicity case averted.”

2. In Table 2, the fourth row “QALY”, the second column should be “10.91” instead of “7.20”, and the third column should be “7.20” instead of “10.91”, the fourth column should be “3.71” instead of “3.70”.
3. In Table 2, the last row titled “ICER, \$ per QALY”, the value should be “\$2,966 (dominant)” instead of “\$1,988 (dominant)”.

This has been corrected in this paper.

The original article can be found online at <https://doi.org/10.1007/s40121-022-00607-x>.

J. Yang · R. J. Dillon (✉)
Merck & Co., Inc., Kenilworth, NJ, USA
e-mail: ryan.dillon@merck.com

J. Naik · M. Massello · L. Ralph
BresMed Health Solutions Ltd, Sheffield, UK

OPEN ACCESS

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to

the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included

in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.